Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics ( (AU:PER) ) has issued an announcement.
Percheron Therapeutics has announced a proposed non-renounceable pro rata offer to existing shareholders, comprising up to 434,975,053 new fully paid ordinary shares and 217,487,526 unquoted options exercisable at A$0.01 within two years of issue. The timetable sets an ex-date of 19 March 2026, a record date of 20 March 2026, offer closing on 8 April 2026 and an issue date of 15 April 2026, signaling a significant capital-raising move that could materially expand the company’s equity base and provide additional funding flexibility.
The structure of the offer, including the attached low-priced options, is likely designed to encourage shareholder participation while potentially increasing future dilution if options are exercised. By opting for a standard non-renounceable pro rata issue, Percheron aims to give existing investors priority access to the new securities, which may help support its balance sheet and advance its therapeutic programs, though it concentrates the opportunity and associated risk within the current shareholder base.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an Australia-based biotechnology company listed on the ASX under the code PER. The company operates in the therapeutics sector, focusing on the development of pharmaceutical or biomedical treatments, and raises capital on public markets to fund its research, development, and corporate activities.
Technical Sentiment Signal: Sell
Current Market Cap: A$6.52M
For a thorough assessment of PER stock, go to TipRanks’ Stock Analysis page.